Pharmacogenomics

The intersection of genomic insight, pharmacologic expertise, and personalized medicine

The right drug, the first time

It is a recognized fact in medicine that individuals vary in their responses to drug therapy. The distinct differences in genetic makeup among individuals significantly influence pharmacokinetic and pharmacodynamic variabilities in drug response.

As a fundamental aspect of precision medicine, pharmacogenomics (PGx) has the potential to identify drug therapy responders and non-responders. This capability guides the creation of individualized treatment plans and dose optimization, aiming to maximize medication effectiveness and minimize toxicities in each patient.

Currently, over 350 medications include pharmacogenomic information in their FDA-approved labels and package inserts.

Aviah Solution
difference

It is estimated that at least 1 in 4 primary care patients are prescribed at least one medication with pharmacogenomic implications

Drugs are therapeutically effective in 20-60% of patients, while approximately 40-75% of patients show no response to initial treatments

According to the FDA, lack of efficacy is common, and serious adverse drug reactions (ADRs) remain a leading cause of morbidity and mortality

The Aviah Your PGX Partner

Our board-certified clinical pharmacists deploy evidence-based PGX information in our pre and post test consultations to physicians and patients. We analyze and distill complex PGX information and create personalized, comprehensive, easy-to-read and actionable reports for prescribers to guide the selection of the therapeutic and cost-effective treatments for patients. We also engage and empower your patients to achieve the best possible outcomes.

The test is only a small piece of the puzzle

A larger and more critical piece is the analysis and clinical application to achieve the desired outcomes.

The Aviah Live Pharmacogenomics Process

Having the patient’s genetic information before prescribing is crucial to the identification and prevention of drug-gene interactions (DGIs), or complex drug-drug-gene interactions (DDGIs) that can occur as a result of the superimposition of drug-drug interactions (DDIs) on drug-gene interactions (DGIs). This is especially the case in high-risk, medically-complex patients on multiple concomitant medications. This process ultimately guides the prospective selection of appropriate and personalized drug therapy for patients.

Benefits of Pharmacogenomics

Benefits of Pharmacogenomics
Mitigate medication-related risks
Improve medication adherence

The right drug, the first time

Over 30% of adults are prediabetic and at risk for developing type 2 diabetes. A proven route to preventing diabetes focuses on better nutrition, being more active, and reducing stress. Yet many Americans struggle to achieve these lifestyle modifications and continue to be at risk for diabetes, heart attack and stroke.